Data for a pair of studies presented at Kidney Week 2023 provide an overview of the effects of eGFR and how this might translate to potential long-term benefit in patients IgA nephropathy.
1. Reduction in time-weighted glomerular filtration rate (GFR) decline was significantly greater in Nefecon versus placebo. 2. Majority of adverse events were mild-to-moderate in nature with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA nephropathy is a chronic immune-mediated kidney disease with marked proteinuria. Nefecon, a novel, targeted-release form of budesonide, is designed
1. Reduction in time-weighted glomerular filtration rate (GFR) decline was significantly greater in Nefecon versus placebo. 2. Majority of adverse events were mild-to-moderate in nature with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA nephropathy is a chronic immune-mediated kidney disease with marked proteinuria. Nefecon, a novel, targeted-release form of budesonide, is
STOCKHOLM, Dec. 30, 2022 /PRNewswire/ Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of